Mina

MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases

Retrieved on: 
Thursday, April 4, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Central nervous system, RNAa, CNS, Therapy, DSM-IV codes, Patient, Biology, RNA, Mina, Pharmaceutical industry

The collaboration will allow for the discovery, and potential development and commercialization of RNAa therapeutic candidates targeting rare neurodegenerative diseases for which there are currently no treatment options.

Key Points: 
  • The collaboration will allow for the discovery, and potential development and commercialization of RNAa therapeutic candidates targeting rare neurodegenerative diseases for which there are currently no treatment options.
  • Under the agreement, MiNA Therapeutics will utilize its proprietary RNAa algorithm and technology platform to identify and characterise RNAa molecules targeting rare genetic diseases of the central nervous system (CNS).
  • Nippon Shinyaku will also have the option to exercise an exclusive license to further research, develop and commercialize pharmaceutical candidates based on early-stage preclinical outcomes.
  • "We are proud and excited to announce this collaboration with Nippon Shinyaku, who have prioritised rare genetic diseases as part of their impressive research and development capabilities,” said Robert Habib, Chief Executive Officer at MiNA.

NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System

Retrieved on: 
Thursday, April 4, 2024
IRP, Central nervous system, Patient, Research, RNA, Mina, RNAa, Therapy, Bone marrow, Pharmaceutical industry

The agreement was facilitated by the NS Pharma Innovation Research Partnering (IRP) team, located in Cambridge, MA.

Key Points: 
  • The agreement was facilitated by the NS Pharma Innovation Research Partnering (IRP) team, located in Cambridge, MA.
  • "We are incredibly proud of our IRP division and the work it is doing with the great team at MiNA Therapeutics," said NS Pharma President Tsugio Tanaka.
  • Through this agreement, MiNA Therapeutics will provide Nippon Shinyaku RNAa therapeutics, which are oligonucleotides that can increase the transcription of a target gene.
  • "Through this research alliance with MiNA Therapeutics, we will continue our efforts to apply our nucleic acid drug technology in the central nervous system," Tanaka stated.

MiNA Therapeutics Presents New Data for its HbF Program at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference

Retrieved on: 
Wednesday, January 24, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Patient, Liposome, Therapy, RNAa, Keystone, MST, RNA, Mina, Fetal hemoglobin, Conference, Bone marrow, Sickle cell disease, Safety, HBF, Vivo, HBG, Pharmaceutical industry

MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, announced today that it will present new pre-clinical data for its lead RNA activation program targeting fetal hemoglobin (HbF) at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference in Banff, Alberta, Canada.

Key Points: 
  • MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, announced today that it will present new pre-clinical data for its lead RNA activation program targeting fetal hemoglobin (HbF) at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference in Banff, Alberta, Canada.
  • The data will be presented on January 24, 2024, at 7:30 pm MST during a poster presentation.
  • MiNA’s HbF program is designed to increase transcription of the gamma globin (HBG) gene, enabling patients with beta-hemoglobinopathies to produce enhanced levels of HbF.
  • MiNA anticipates advancing its HbF program, the first program to emerge from its genetic medicine portfolio, into pre-clinical development in 2024.

MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Retrieved on: 
Wednesday, October 25, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Mina, OTS, Acute myeloid leukemia, Therapy, RNA, Bone marrow, Cell, RNAa, Inherit, Gene, Oligonucleotide, AML, Regulation, Vaccine

MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Key Points: 
  • MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
  • RNAa therapeutics are a revolutionary new class of medicines that can restore or boost normal function of genes and thereby protein-modulated pathways in cells.
  • Another study titled, “Small-Activating RNA Therapy Development for the Inherited genetic Disorder Aniridia,” revealed the potential of RNAa therapeutics to treat a rare and severe genetic eye disease.
  • “The findings from these three preclinical studies demonstrate continued advances in the development of our novel RNAa therapeutics across a range of therapeutic areas,” said Robert Habib, CEO of MiNA Therapeutics.

MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic Diseases

Retrieved on: 
Tuesday, April 25, 2023
Biotechnology, Health, Genetics, Science, Research, RNAa, Partnership, Therapy, Senior, BioMarin Pharmaceutical, Mina, DSM-IV codes, RNA, Protein, Patient, Biology, Pharmaceutical industry, Vaccine

MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a multi-target research collaboration and option licensing agreement with BioMarin Pharmaceutical Inc.

Key Points: 
  • MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a multi-target research collaboration and option licensing agreement with BioMarin Pharmaceutical Inc.
  • The collaboration will allow for the discovery, and potential development and commercialization of RNAa therapeutic candidates targeting a number of rare genetic diseases.
  • Under the agreement, BioMarin will employ MiNA Therapeutics’ proprietary RNAa algorithm and technology platform to identify and characterize RNAa molecules targeting a number of genetic diseases for which there are currently no or minimal therapeutic options.
  • "We are proud to announce this collaboration with BioMarin, a global leader in the development and commercialization of treatments for rare genetic diseases,’’ said Robert Habib, Chief Executive Officer at MiNA.

MiNA Therapeutics Presents Late-Breaking Positive Phase 1b Data for MTL-CEBPA in Combination with an Anti-PD1 Checkpoint Inhibitor at the Annual American Association of Cancer Research (AACR) Meeting

Retrieved on: 
Friday, April 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, RNAa, Myelocyte, Interim, AACR, Therapy, Mina, Neoplasm, MTL, Cancer, RNA, EDT, Liver cancer, Patient, Sorafenib, American Association for Cancer Research, Pembrolizumab, Tumor microenvironment, HCC, Safety, Pharmaceutical industry, Vaccine

Findings from the Phase 1b portion of the study validate the clinical proof of mechanism of MTL-CEBPA as a combination treatment and identify a novel predictive biomarker of clinical response.

Key Points: 
  • Findings from the Phase 1b portion of the study validate the clinical proof of mechanism of MTL-CEBPA as a combination treatment and identify a novel predictive biomarker of clinical response.
  • The data will be presented on Tuesday, April 18, during a late-breaking research session beginning at 9:00 am EDT.
  • MTL‑CEBPA is the first therapy that specifically up-regulates CCAAT/enhancer binding protein alpha (C/EBP-α), a transcription factor that acts as a master regulator of myeloid cells.
  • Interim data from an open-label, multi-center study demonstrated the safety, tolerability, immunological and clinical activity of MTL-CEBPA in combination with pembrolizumab.

ARTIST FABIN RASHEED AND NEUROSCIENTIST MURALI DORAISWAMY TO RELEASE NFT TO RAISE AWARENESS OF MENTAL WELLBEING AT ART DUBAI

Retrieved on: 
Tuesday, February 28, 2023
Creativity, Love, Sculpture, Depression, Nifty Gateway, Brain, NFT, Human, EEG, Nature, Sale, Woman, Mina, Pharmaceutical industry

Featuring a composite brain EEG recording of the artist during recovery from depression, it spotlights the importance of connectedness, self-efficacy and love in healing.

Key Points: 
  • Featuring a composite brain EEG recording of the artist during recovery from depression, it spotlights the importance of connectedness, self-efficacy and love in healing.
  • MEMORIA can be viewed in 3D/AR and will be available for sale starting March 1, 2023 at Nifty Gateway's website .
  • Fabin and Dr. Doraiswamy hope their collaboration serves to raise awareness of the importance of mental wellbeing and flourishing to individuals and society.
  • Art Dubai, one of the world's leading art fairs, takes place March 1-5, 2023 in Dubai, UAE.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2022

Retrieved on: 
Tuesday, February 14, 2023
D, GPCR, KU Leuven, Immunotherapy, Genentech, Glutamate (neurotransmitter), Investment, Inflammatory bowel disease, EP4, DSM-IV codes, Pfizer, Cancer, Obesity, Cancer Research UK, Patient, Schizophrenia, University, Diabetes, Research, G&A, Therapy, Anxiety, Takeda, IBD, USD, Mina, FDA, Growth, Neurocrine Biosciences, Drug discovery, AbbVie, NAM, CRUK, Fine chemical, Pharmaceutical industry, Vaccine, Bank, Cryptocurrency, Lilly, JPY

Sosei Heptares received an upfront payment of US$37 million and is eligible to receive milestones totalling up to US$694 million, plus tiered royalties on global sales.

Key Points: 
  • Sosei Heptares received an upfront payment of US$37 million and is eligible to receive milestones totalling up to US$694 million, plus tiered royalties on global sales.
  • PF-07081532 was discovered by Pfizer during a multi-target research collaboration in which its scientists had access to Sosei Heptares’ StaR® technology.
  • Clinical development agreement with Cancer Research UK – to advance Sosei Heptares’ immunotherapy candidate HTL0039732 into a Phase 1/2a trial.
  • Cash and cash equivalents as at 31 December 2022 increased by JPY 6,470 million from the beginning of the year and amounted to JPY 66,557 million.

Sierra Metals Reports Consolidated Financial Results for the First Quarter Of 2022

Retrieved on: 
Wednesday, May 11, 2022
Mining, Minerals, Natural Resources, Copper, Income, Company, Movement, EBITDA, CUS, MD, Lead, Multimedia, Gold, Metal, COVID-19, Mina, TSX, Silver, Bolivar, West Virginia, Zinc, SMTS, Sierra (metal band), Mining, AISC, SMT, NYSE, BVL, Printed circuit board, Lithium, Mobile phone, Bolívar (disambiguation)

The Bolivar Mine processed 187,556 tonnes in Q1 2022, representing a 50% decrease from tonnes processed in Q1 2021.

Key Points: 
  • The Bolivar Mine processed 187,556 tonnes in Q1 2022, representing a 50% decrease from tonnes processed in Q1 2021.
  • The decrease in throughput and grades resulted in a 64% decrease in copper equivalent pounds produced during Q1 2022 as compared to Q1 2021.
  • Revenue from metals payable of $57.2 million in Q1 2022 decreased by 18% from $69.6 million in Q1 2021.
  • The decrease in adjusted EBITDA in Q1 2022 resulted from lower revenues and lower gross margins as compared to Q1 2021.

MiNA Therapeutics Presents Proof of Mechanism Data on MTL-STING as a Novel Cancer Immunotherapy

Retrieved on: 
Monday, April 11, 2022
Oncology, Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Cell, Therapy, Sorafenib, RNA activation, AACR, American Association, Cancer, RNA, STING, Immune system, Lists of diseases, Association, Safety, Technology, Mina, Liver cancer, MTL, Gene, HCC, Escape Room, Patient, Vaccine, Pharmaceutical industry

MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA (RNAa) therapeutics, presents preclinical proof of mechanism data on MTLSTING as a novel cancer immunotherapy.

Key Points: 
  • MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA (RNAa) therapeutics, presents preclinical proof of mechanism data on MTLSTING as a novel cancer immunotherapy.
  • The data validates the drug candidates ability to upregulate the STING protein and related downstream pathways of innate immunity through gene activation.
  • We are very pleased to present this encouraging data and to advance MTL-STING further in development.
  • Upregulating STING presents a novel therapeutic approach to address immune evasion and improve the effectiveness of existing immunotherapies in cancer patients.